TABLE 2.

Treatment-related adverse events and in-hospital stay during 6 months’ follow-up

	ELVR	No-ELVR	LVRS
Subjects	20	18	16
Adverse event
Pneumothorax	2 (10)	0 (0)	1 (6)
Heimlich valve	0	NA	4 (25)
Event requiring bronchoscopy#	7 (35)	0 (0)	2 (13)
Moderate respiratory event¶	12 (60)	12 (67)	3 (19)
Severe respiratory event+	9 (45)	5 (28)	13 (81)
Death	0 (0)	1 (6)	1 (6)
In-hospital stay days
For intervention	5 (5–55)	NA	14.5 (7–61)
During follow-up§	10 (6–14)	16 (10–33)	7.5 (2–77)

Data are presented as n, n (%) or median (range). ELVR: endoscopic lung volume reduction; NA: not applicable. ^#: endobronchial valves removal (pneumothorax; no treatment benefit; valve dislocation), symptomatic bronchial impaction; ^¶: event with need for medication, but no hospitalisation required (acute exacerbation of COPD, any lower respiratory tract infection); ⁺: event with need for repeat bronchoscopy, prolonged hospitalisation with chest tube (due to pneumothorax, post-operative pulmonary air leak or subcutaneous emphysema) or medication and hospitalisation required (due to acute exacerbation of COPD, any lower respiratory tract infection, acute pulmonary embolism); ^§: ELVR n=6 (30%), no-ELVR n=5 (28%), LVRS n=4 (25%) hospitalised during 6 months’ follow-up.